Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision
oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA) …

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …